BLUEJAY DIAGNOSTICS O.N.

Bluejay has prematurely completed patient recruitment for the prospective, multicenter SYMON‑II study with 750 enrolled patients. The study is evaluating the Symphony IL‑6 test to assess 28‑day mortality risk in ICU patients with sepsis; initial data indicate a 28‑day mortality of around 17%. Bluejay plans to complete data cleaning, statistical analysis and reporting in the coming months and to use the results to support a 510(k) submission to the FDA; the Symphony platform is currently an investigational product without regulatory approval. » More on de.investing.com

Bluejay Diagnostics completed a private placement raising $8.5 million, selling 3,655,917 common shares or pre-funded warrants at $2.325 each. It also issued immediately exercisable Series G and H warrants with an exercise price of $2.075 (Series G five years, Series H 24 months); full cash exercise of these could generate additional gross proceeds of about $15.2 million. The company expects net proceeds to extend its cash runway into the first quarter of 2027 and plans to use the funds for FDA approval activities, clinical trials, R&D and general working capital; the stock rose sharply after the announcement. » More on de.investing.com

Bluejay Diagnostics released results for the fiscal year ended December 31, 2025, and reported a loss per share of $15.25. In the prior year the loss was -$456.76 per share. » More on finanzen.net